Deng Lucy, Van Eldik Amanda, O'Moore Megan, Buttery Jim, Cheung Abigail, Cox Nicholas, Drake-Brockman Carla, Dwyer Nathan, Effler Paul, Gold Michael, Hissaria Pravin, Kelly Andrew, Khanlari Sarah, Larter Claire, Melody Shannon, Nissen Michael, Puranik Rajesh, Rankin James, Singleton Sally, Thomas Liza, Wahi Sudhir, Wheaton Gavin, Zentner Dominica, Macartney Kristine, Chow Clara K, Wood Nicholas
National Centre for Immunisation Research and Surveillance, Children's Hospital at Westmead, Westmead, NSW, Australia.
The University of Sydney Children's Hospital Westmead Clinical School, Westmead, NSW, Australia.
NPJ Vaccines. 2025 Jul 16;10(1):155. doi: 10.1038/s41541-025-01206-w.
Clinical progression and medium-long term morbidity from myocarditis following mRNA COVID-19 vaccinations remains an important but undefined public health concern. We conducted prospective follow-up of individuals with either confirmed or probable myocarditis following monovalent Pfizer-BioNTech BNT162b2 or Moderna mRNA-1273 vaccination between 21 April 2021 and 5 July 2022 in Australia. Of 256 individuals who consented to follow up, mostly males following a second dose, 60% (133/221) had ongoing symptoms at 3-6 months and 35% (81/231) at 12-18 months. Self-reported ongoing exercise restrictions, medication requirements, and hospital re-presentations were associated with ongoing symptoms, as was a lower self-reported health status and quality of life. Clinical severity remained mild, with low hospitalisation rates and no deaths in the follow-up period and health-related quality of life improved over time. These findings support ongoing use of mRNA COVID-19 vaccines in at-risk individuals to prevent disease caused by SARS-CoV-2 infection.
mRNA新冠疫苗接种后心肌炎的临床进展及中长期发病率仍是一个重要但尚不明确的公共卫生问题。2021年4月21日至2022年7月5日期间，我们在澳大利亚对接种了单价辉瑞-生物科技公司的BNT162b2或莫德纳公司的mRNA-1273疫苗后确诊或疑似心肌炎的个体进行了前瞻性随访。在256名同意接受随访的个体中，大多数为接种第二剂疫苗后的男性，60%（133/221）在3至6个月时有持续症状，35%（81/231）在12至18个月时有持续症状。自我报告的持续运动限制、药物需求和再次住院与持续症状相关，自我报告的健康状况和生活质量较低也与之相关。临床严重程度仍为轻度，随访期间住院率低且无死亡病例，与健康相关的生活质量随时间推移有所改善。这些发现支持在高危个体中持续使用mRNA新冠疫苗以预防由SARS-CoV-2感染引起的疾病。
